Objective: To analyze the application value of modified endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) in rectal neuroendocrine tumors, with a view to providing new clinical options for the early diagnosis and treatment of patients with such tumors, and thus improving their prognosis. Methods: Seventy-two patients with rectal neuroendocrine tumors who underwent surgical treatment in a hospital between October 2023 and September 2024 were selected and divided into a control group and an observation group using the mean score method, each with 36 cases. In the control group, traditional foreign body forceps combined with laparoscopic resection were performed, and in the observation group, modified EMR and ESD were performed as needed. The mass resection rate, histologically intact resection rate, postoperative serum vascular endothelial growth factors (VEGFA, VEGFB, VEGFC levels) in the postoperative period of 7d, and indicators of the rate of related complications of the two groups of patients were compared. Results: The mass resection rate of 91.67% and histological complete resection rate of 94.44% in the observation group were significantly higher than those of 72.22% and 66.67% in the control group; the VEGFA, VEGFB, and VEGFC levels of the observation group were 82.08 ± 7.94 ng/ml, 168.89 ± 16.53 ng/ml, and 121.07 ± 10.75 ng/ml, respectively, in the postoperative period of 7 d after surgery; the levels were significantly higher than those of the control group: 68.39 ± 6.82 ng/ml, 141.06 ± 14.12 ng/ml, and 98.45 ± 9.87 ng/ml, respectively, and the difference was statistically significant (P < 0.05); the patients in the observation group had a lower rate of surgical complications than those in the control group (2.78% vs 8.33%), the difference was not statistically significant (P > 0.05). Conclusion: Modified EMR and ESD in rectal neuroendocrine tumors are effective, not only can it effectively improve the rate of mass resection and histological integrity of the resection rate, but it can also further improve the level of serum vascular endothelial growth factor (VEGFA, VEGFB, VEGFC); thus, it is recommended to be promoted for use in clinical practice.
Luo P, Liu A, Yi C, et al., 2025, Analysis of the Effect of Ultrasonic Endoscopy Combined with Modified Endoscopic Mucosal Resection in the Treatment of Rectal Neuroendocrine Tumors. Chongqing Medical Journal, OnlineFirst, 1–10.
Wang O, Fu YC, Zhang JC, et al., 2024, Meta-Analysis of the Efficacy of Endoscopic Mucosal Resection with Ligation Device Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors (less than or equal to 10 mm). Chinese Journal of Endoscopy, 30(12): 43–54.
Gui G, Wang H, Yi J, et al., 2024, Clinical Study of Endoscopic Submucosal Dissection Guided by Endoscopic Ultrasonography for the Treatment of Patients with Rectal Neuroendocrine Tumors. Cancer Progress, 22(08): 877–880.
Zhang L, Liu M, Li Q, et al., 2024, Modified Endoscopic Mucosal Resection in Rectal Neuroendocrine Tumors. Journal of Gastroenterology and Hepatology, 33(02): 218–222.
Gao X, 2023, Randomized Controlled Clinical Study of Modified Transparent Cap-Assisted Endoscopic Submucosal Resection Versus Endoscopic Submucosal Dissection for the Treatment of Rectal Neuroendocrine Tumors less than or equal to 10 mm, dissertation, Southern Medical University.
Cao Y, Zhuang D, Xing Y, et al., 2022, Analysis of the Efficacy of Different Endoscopic Approaches for the Treatment of Rectal Neuroendocrine Tumors. Chinese Journal of Endoscopy, 28(11): 48–56.
Jin Y, Zhou J, Zhao J, et al., 2022, Analysis of Factors Affecting Incomplete Resection and Positive Vertical Margins of Specimens after ESD in Patients with Rectal Neuroendocrine Tumors. Journal of Bengbu Medical College, 47(10): 1397–1400 + 1406.
Luo L, 2022, Analysis of Risk Factors for Non-Curative Resection of Rectal Neuroendocrine Tumors Treated by Transendoscopic Submucosal Dissection, dissertation, Shihezi University.
Cui J, 2022, Clinical Effect of Endoscopic Submucosal Dissection in the Treatment of Rectal Neuroendocrine Tumors. Jilin Medicine, 43(03): 676–678.
Yang DJ, 2021, Endoscopic Submucosal Dissection of Rectal Neuroendocrine Tumors. Journal of Digestive Oncology (Electronic Edition), 13(01): 83–84.